Clinical Trials Logo

Clinical Trial Summary

Blood samples from urticaria patients will be analyzed for viral particles


Clinical Trial Description

After digestion with DNase to eliminate human DNA, RNA will be reversed-transcribed and amplified with random primer/ Amplification products will be pooled and sequenced/ After substruction of sequences of vertebrates and highly repetitive sequences, contiguous sequences will be assembled and compared with motifs represented in databases of viruses. which will enable identification of putative protein sequences consistent with viruses ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03151902
Study type Observational
Source HaEmek Medical Center, Israel
Contact Menachem Rottem, MD
Phone +972-528617823
Email rottem_me@clalit.org.il
Status Recruiting
Phase
Start date July 2, 2017
Completion date September 30, 2023

See also
  Status Clinical Trial Phase
Completed NCT03111628 - Role of Immunoglobulin E (IgE) Bearing Cells in Chronic Idiopathic Urticaria (CIU) Phase 4
Completed NCT03632291 - Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of UB-221 as an Add-on Therapy in CSU Patients Phase 1
Completed NCT05461456 - Bioavailability and Tolerability of Fexofenadine Hydrochloride Topical Lotion 1% Phase 1